Shady Mohammed Abdelhalim <br/><br/>
Fast dissolving systems for an angiotensin receptor blocker /  
 أنظمة سريعة الذوبان لعقار غالق لمستقبلات الأنجيوتنسين 
Shady Mohammed Abdelhalim ; Supervised Nabaweya Abdelaziz , Omaima Naim Elgazayerly , Maha Mohammed Amin 
 - Cairo :   Shady Mohammed Abdelhalim ,   2015 
 - 267 P. :   charts ;   25cm 
<br/><br/>Thesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics 
<br/><br/> From the obtained results, it was possible to conclude the following:  1. After oral administration of Disartan capsule and LS-SNEDDS formula (A18)  with dose equivalent to 30 mg Valsartan/ kg rat, the mean value of the plasma  peak concentration (Cpmax) was found to be 8.26 ± 1.24 æg/ml and 14.38 ± 1.45  æg/ml respectively attained after tmax of 1.50 hr. and 0.50 hr. respectively.  2. The bioavailability of Valsartan from LS-SNEDDS relative to Disartan capsule  was found to be 218.97 %.  3. The LS-SNEDDS formula (A18), showed extremely significant increase in  Cpmax (1.74 fold) and AUC(0-) (2.19 fold).  4. The desired enhancement of bioavailability of Valsartan from LS-SNEDDS was  achieved via the observed shorter tmax as an indication of absorption rate and  increase in the extent of drug absorption as indicated by the area under plasma  concentration curve with a percentage relative bioavailability 218.97 %.  Finally, LS-SNEDDS succeeded in enhancing Valsartan dissolution more  significantly than liquid SNEDDS and S-SNEDDS due to the fact that LS- SNEDDS exhibited lager surface area exposed to the dissolution media.  Therefore, the formulation of Valsartan as LS-SNEDDS could be a promising  technique in improving its dissolution, bypassing first pass metabolism and  thereby its bioavailability 
<br/><br/>
<br/><br/><label>Subjects--Index Terms: </label>Angiotensin receptor blocker Fast dissolving systems Pharmaceutics